Lung Cancer Therapeutics: Global Markets
Report Scope:
This report provides a detailed analysis of prevailing lung cancer treatment guidelines in different geographic regions. This report looks at lung cancer therapeutics market revenue by disease type (i.e., NSCLC and SCLC) and the proportion of chemotherapeutics and targeted therapies used for treating each disease type in different geographic regions. Non-pharmaceutical treatment segments like radiation and surgery are excluded from this report. Lung cancer therapeutic market data is present for 2017 and for the forecast period, which is 2018 to 2023. The market data provided in this report are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Detailed lung cancer therapeutic market analyses are presented for five regions: North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
Global market drivers, trends and challenges affecting the lung cancer therapeutics market are presented in this report. Detailed analyses of the competitive environments, pipeline analysis, patents, regulatory landscape and reimbursement landscape are included in the report.
Report Includes:
This report provides a detailed analysis of prevailing lung cancer treatment guidelines in different geographic regions. This report looks at lung cancer therapeutics market revenue by disease type (i.e., NSCLC and SCLC) and the proportion of chemotherapeutics and targeted therapies used for treating each disease type in different geographic regions. Non-pharmaceutical treatment segments like radiation and surgery are excluded from this report. Lung cancer therapeutic market data is present for 2017 and for the forecast period, which is 2018 to 2023. The market data provided in this report are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Detailed lung cancer therapeutic market analyses are presented for five regions: North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
Global market drivers, trends and challenges affecting the lung cancer therapeutics market are presented in this report. Detailed analyses of the competitive environments, pipeline analysis, patents, regulatory landscape and reimbursement landscape are included in the report.
Report Includes:
- 34 data tables and 32 additional tables
- An in-depth overview of the global market for lung cancer therapeutics within the industry
- Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Identification of key market dynamics, trends, opportunities and factors influencing the global lung cancer drug technology
- Assessment of major regulatory pathways and hurdles faced by lung cancer therapeutic product manufacturers
- Information pertaining to lung cancer drug patent applications, expirations and the latest key technology developments, pipeline analysis, reimbursement scenarios, and unmet needs associated with the market
- Dossier of mergers and acquisitions, new product development, strategies, research and development activities of major market players
- Examination of competitive landscape for the lung cancer therapeutics market, and information pertaining to leading lung cancer market players, their marketed products, pipeline products and product patent expirations
- Detailed company profiles of major manufacturers of oncology products, including Bayer AG, Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Novartis International AG and Pfizer Inc.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Introduction
Lung Cancer Types
In Situ Lung Cancer
Malignant Lung Tumors
Stages of Lung Cancer
Staging of NSCLC
Staging of SCLC
Risk Factors
Tobacco Smoking
Second-Hand Smoking (SHS)
Exposure to Asbestos
Exposure to Other Elements
Family History
Personal History
Lung Cancer Symptoms
Symptoms of Tumor Growth in the Lungs and Chest
Symptoms Caused by Metastases Beyond the Chest
Symptoms Caused by Tumor Secretion
Lung Cancer Diagnosis
General Screening Tests
Lung Cancer Management
Radiation Therapy
Chemotherapy
Surgery
Targeted Therapy for Lung Cancer
Immunotherapy for Lung Cancer
Palliative Treatment for Lung Cancer
CHAPTER 4 MARKET DYNAMICS
Market Drivers
Global Increase in Lung Cancer Incidence
Increase in Healthcare Expenditures and Government Funding in Key Countries
Robust Clinical Drug Pipeline
Increasing Life Expectancy of Lung Cancer Patients
Surge in Female Smokers
Market Restraints
Patent Expiration of Key Drug Molecules
Regulatory and Reimbursement Hurdles
Available Low-Priced Chemotherapeutics Limiting Growth of Advanced Therapies
Market Opportunities
Highest Incidence of Lung Cancer in Asia-Pacific
Increasing Demand for Targeted Therapies (EGFR or ALK Inhibitors, TKIs)
Increasing Incidence of NSCLC and its Non-responsiveness to Chemotherapy
Increasing Lung Cancer Incidence Among Non-Smokers
Clinical Trial Failures
CHAPTER 5 MARKET BREAKDOWN BY LUNG CANCER TYPE
Market Overview
Market Size and Forecast
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
CHAPTER 6 MARKET BREAKDOWN BY REGION
Epidemiology of Lung Cancer
Global Market for Lung Cancer Therapeutics by Region
North America
Europe
Asia-Pacific
Middle East and Africa
South America
CHAPTER 7 REIMBURSEMENT LANDSCAPE
Introduction
United States
Lung Cancer Drug Reimbursement
Germany
Lung Cancer Drug Reimbursement
Brazil
China
CHAPTER 8 PATENT REVIEW
Patents Granted
Patent Expiration
CHAPTER 9 REGULATORY LANDSCAPE
Regulatory Challenges for Lung Cancer Therapeutics
North America
United States
Canada
Mexico
Europe
Mutual Recognition Procedure
Decentralized Procedure
Centralized Procedure
Asia-Pacific
Japan
China
India
South Korea
Middle East and Africa
Saudi Arabia
South Africa
South America
Brazil
Argentina
CHAPTER 10 COMPETITIVE LANDSCAPE
Major Lung Cancer Drug Companies
Eli Lilly and Co.
AstraZeneca Pharmaceuticals
Pfizer Inc.
CHAPTER 11 PIPELINE ANALYSIS
Introduction
Late-Stage Pipeline Drug Candidates
JAK Inhibitors for Lung Cancer
Third-Generation EGFR TKIs
CHAPTER 12 COMPANY PROFILES
ABBVIE INC.
Company Overview
Financials
Product Information
Development and Strategies
AMGEN INC.
Company Overview
ASTELLAS PHARMA INC.
Financials
ASTRAZENECA PLC
Company Overview
Financials
Products and Services
Developments and Strategies
BAYER AG
Company Overview
Financials
Product Information
BETA PHARMA INC.
Business Overview
Products and Services
BOEHRINGER INGELHEIM GMBH
Company Overview
Financials
Products and Services
Development and Strategies
BRISTOL-MYERS SQUIBB CO.
Company Overview
Financials
Products and Services
CELGENE CORP.
Company Overview
Financials
Products and Services
DAIICHI SANKYO CO., LTD.
Company Overview
Financials
Product and Services
ELI LILLY AND CO.
Company Overview
Financials
F. HOFFMANN-LA ROCHE AG
Company Overview
Financials
Products and Services
MERCK & CO., INC.
Company Overview
Financials
Products and Services
Development and Strategies
NOVARTIS INTERNATIONAL AG
Company Overview
Financials
Products and Services
Development and Strategies
PFIZER INC.
Company Overview
Financials
Product Information
Development and Strategies
TAKEDA PHARMACEUTICALS CO.
Company Overview
CHAPTER 13 APPENDIX: ACRONYMS
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Introduction
Lung Cancer Types
In Situ Lung Cancer
Malignant Lung Tumors
Stages of Lung Cancer
Staging of NSCLC
Staging of SCLC
Risk Factors
Tobacco Smoking
Second-Hand Smoking (SHS)
Exposure to Asbestos
Exposure to Other Elements
Family History
Personal History
Lung Cancer Symptoms
Symptoms of Tumor Growth in the Lungs and Chest
Symptoms Caused by Metastases Beyond the Chest
Symptoms Caused by Tumor Secretion
Lung Cancer Diagnosis
General Screening Tests
Lung Cancer Management
Radiation Therapy
Chemotherapy
Surgery
Targeted Therapy for Lung Cancer
Immunotherapy for Lung Cancer
Palliative Treatment for Lung Cancer
CHAPTER 4 MARKET DYNAMICS
Market Drivers
Global Increase in Lung Cancer Incidence
Increase in Healthcare Expenditures and Government Funding in Key Countries
Robust Clinical Drug Pipeline
Increasing Life Expectancy of Lung Cancer Patients
Surge in Female Smokers
Market Restraints
Patent Expiration of Key Drug Molecules
Regulatory and Reimbursement Hurdles
Available Low-Priced Chemotherapeutics Limiting Growth of Advanced Therapies
Market Opportunities
Highest Incidence of Lung Cancer in Asia-Pacific
Increasing Demand for Targeted Therapies (EGFR or ALK Inhibitors, TKIs)
Increasing Incidence of NSCLC and its Non-responsiveness to Chemotherapy
Increasing Lung Cancer Incidence Among Non-Smokers
Clinical Trial Failures
CHAPTER 5 MARKET BREAKDOWN BY LUNG CANCER TYPE
Market Overview
Market Size and Forecast
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
CHAPTER 6 MARKET BREAKDOWN BY REGION
Epidemiology of Lung Cancer
Global Market for Lung Cancer Therapeutics by Region
North America
Europe
Asia-Pacific
Middle East and Africa
South America
CHAPTER 7 REIMBURSEMENT LANDSCAPE
Introduction
United States
Lung Cancer Drug Reimbursement
Germany
Lung Cancer Drug Reimbursement
Brazil
China
CHAPTER 8 PATENT REVIEW
Patents Granted
Patent Expiration
CHAPTER 9 REGULATORY LANDSCAPE
Regulatory Challenges for Lung Cancer Therapeutics
North America
United States
Canada
Mexico
Europe
Mutual Recognition Procedure
Decentralized Procedure
Centralized Procedure
Asia-Pacific
Japan
China
India
South Korea
Middle East and Africa
Saudi Arabia
South Africa
South America
Brazil
Argentina
CHAPTER 10 COMPETITIVE LANDSCAPE
Major Lung Cancer Drug Companies
Eli Lilly and Co.
AstraZeneca Pharmaceuticals
Pfizer Inc.
CHAPTER 11 PIPELINE ANALYSIS
Introduction
Late-Stage Pipeline Drug Candidates
JAK Inhibitors for Lung Cancer
Third-Generation EGFR TKIs
CHAPTER 12 COMPANY PROFILES
ABBVIE INC.
Company Overview
Financials
Product Information
Development and Strategies
AMGEN INC.
Company Overview
ASTELLAS PHARMA INC.
Financials
ASTRAZENECA PLC
Company Overview
Financials
Products and Services
Developments and Strategies
BAYER AG
Company Overview
Financials
Product Information
BETA PHARMA INC.
Business Overview
Products and Services
BOEHRINGER INGELHEIM GMBH
Company Overview
Financials
Products and Services
Development and Strategies
BRISTOL-MYERS SQUIBB CO.
Company Overview
Financials
Products and Services
CELGENE CORP.
Company Overview
Financials
Products and Services
DAIICHI SANKYO CO., LTD.
Company Overview
Financials
Product and Services
ELI LILLY AND CO.
Company Overview
Financials
F. HOFFMANN-LA ROCHE AG
Company Overview
Financials
Products and Services
MERCK & CO., INC.
Company Overview
Financials
Products and Services
Development and Strategies
NOVARTIS INTERNATIONAL AG
Company Overview
Financials
Products and Services
Development and Strategies
PFIZER INC.
Company Overview
Financials
Product Information
Development and Strategies
TAKEDA PHARMACEUTICALS CO.
Company Overview
CHAPTER 13 APPENDIX: ACRONYMS
LIST OF TABLES
Summary Table: Global Market for Lung Cancer Therapeutics, by Type, Through 2023
Table 1: TNM Classification of Malignant Tumors of Lung Cancer
Table 2: Five-Year Survival Rates, NSCLC and SCLC
Table 3: Targeted Therapy for Lung Cancer
Table 4: Targeted Antibodies Used in Lung Cancer
Table 5: Immunomodulators Used in Lung Cancer
Table 6: CAR T-Cell Therapy Clinical Trials Under Investigation
Table 7: Comparison of Overall Estimated Number of New Cancer Cases, by Type, 2018
Table 8: Age-Standardized Lung Cancer Incidence Rate, Rankings by Country, 2017
Table 9: Age-Standardized Lung Cancer Incidence Rate in Men, Rankings by Country, 2017
Table 10: Age-Standardized Lung Cancer Incidence Rate in Women, Ranking by Country, 2017
Table 11: Lung Cancer Incidence in Key Countries, 2017
Table 12: Proportion of Daily Cigarette Smokers in Europe, by Gender, 2014
Table 13: Patent Expiration of Lung Cancer Drugs
Table 14: Incidence of Lung Cancer in Asia-Pacific, 2016
Table 15: Prominent Drugs to Treat Lung Cancer
Table 16: Global Market for Lung Cancer Therapeutics, by Type, Through 2023
Table 17: Global Market for Lung Cancer Therapeutics, by Region, Through 2023
Table 18: Estimated Lung Cancer Statistics for Canada, 2017
Table 19: Lung Cancer Incidence in Canada, Male and Female
Table 20: Overall Healthcare Expenditures in Europe, by Country, Through 2015
Table 21: Number of New Lung Cancer Cases in the U.K., by Gender, 2015
Table 22: Medicare Part B: Lung Cancer Drug Payment Limits, 2018
Table 23: Lung Cancer Drug Reimbursement in Germany, 2018
Table 24: Oncology Drugs Covered by China's National Insurance
Table 25: U.S. Patents on Lung Cancer Therapeutics, 2001-2018
Table 26: Patent Expiration of Lung Cancer Drugs
Table 27: List of FDA-Approved Drugs, Through 2018
Table 28: Lung Cancer Drugs Approved by Health Canada, Through 2018
Table 29: NSCLC Drugs Authorized by the EMA, Through 2018
Table 30: NSCLC Drugs Pending Approval by the EMA, Through 2018
Table 31: NSCLC Drugs Withdrawn by the EMA, Through 2018
Table 32: NSCLC Drugs Pending Application Withdrawal by the EMA, Through 2018
Table 33: SCLC Drugs Pending Withdrawal by the EMA, Through 2018
Table 34: Global Ranking of Lung Cancer Drug Companies, 2017
Table 35: Eli Lilly and Co.: Lung Cancer Marketed Products and Investigational Molecules, Through 2018
Table 36: AstraZeneca Pharmaceuticals: Lung Cancer Marketed Products and Investigational Molecules, Through 2018
Table 37: Lung Cancer Pipeline Drugs, Through 2018
Table 38: Clinical Efficacy of Select Third-Generation EGFR TKIs in Clinical Development
Table 39: AbbVie Inc.: Net Revenue, 2015-2017
Table 40: AbbVie Inc.: Lung Cancer Pipeline
Table 41: Astellas Pharma Inc.: Net Revenue, 2013-2017
Table 42: Astellas Pharma Inc.: Net Revenue, by Country/Region, 2014-2017
Table 43: AstraZeneca Plc: Net Revenue, 2014-2017
Table 44: AstraZeneca Plc: Marketed Products, 2018
Table 45: Bayer AG: Net Revenue, 2015-2017
Table 46: Bayer AG: Lung Cancer Pipeline Molecules
Table 47: Boehringer Ingelheim GmbH: Net Revenue, 2014-2016
Table 48: Boehringer Ingelheim GmbH: Marketed Product, 2018
Table 49: Bristol-Myers Squibb: Net Revenue, 2014-2016
Table 50: Bristol-Myers Squibb: Marketed Products, 2018
Table 51: Celgene Corp.: Net Revenue, 2015-2016
Table 52: Daiichi Sankyo Co., Ltd.: Net Revenue, 2015-2017
Table 53: Eli Lilly and Co.: Net Revenue, 2014-2017
Table 54: Eli Lilly and Co.: Net Revenue, by Segment, 2014-2016
Table 55: Eli Lilly and Co.: Net Revenue, by Oncology Drug, 2014-2016
Table 56: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, Through 2017
Table 57: Tarceva: Drug Revenue, by Country/Region, 2016-2017
Table 58: Merck & Co., Inc.: Net Revenue, 2014-2016
Table 59: Novartis International AG: Net Revenue, by Segment, Through 2017
Table 60: Novartis International AG: Oncology Drugs Revenue, 2015-2017
Table 61: Pfizer Inc.: Net Revenue, 2014-2017
Table 62: Pfizer Inc.: Oncology Drug Revenue, 2015-2017
Table 63: Pfizer Inc.: Oncology Drugs Revenue, 2015-2017
Table 64: Pfizer Inc.: Lung Cancer Marketed Products and Investigational Drug Candidates, 2018
Table 65: Acronyms Used in Global Lung Cancer Therapeutics Market
Summary Table: Global Market for Lung Cancer Therapeutics, by Type, Through 2023
Table 1: TNM Classification of Malignant Tumors of Lung Cancer
Table 2: Five-Year Survival Rates, NSCLC and SCLC
Table 3: Targeted Therapy for Lung Cancer
Table 4: Targeted Antibodies Used in Lung Cancer
Table 5: Immunomodulators Used in Lung Cancer
Table 6: CAR T-Cell Therapy Clinical Trials Under Investigation
Table 7: Comparison of Overall Estimated Number of New Cancer Cases, by Type, 2018
Table 8: Age-Standardized Lung Cancer Incidence Rate, Rankings by Country, 2017
Table 9: Age-Standardized Lung Cancer Incidence Rate in Men, Rankings by Country, 2017
Table 10: Age-Standardized Lung Cancer Incidence Rate in Women, Ranking by Country, 2017
Table 11: Lung Cancer Incidence in Key Countries, 2017
Table 12: Proportion of Daily Cigarette Smokers in Europe, by Gender, 2014
Table 13: Patent Expiration of Lung Cancer Drugs
Table 14: Incidence of Lung Cancer in Asia-Pacific, 2016
Table 15: Prominent Drugs to Treat Lung Cancer
Table 16: Global Market for Lung Cancer Therapeutics, by Type, Through 2023
Table 17: Global Market for Lung Cancer Therapeutics, by Region, Through 2023
Table 18: Estimated Lung Cancer Statistics for Canada, 2017
Table 19: Lung Cancer Incidence in Canada, Male and Female
Table 20: Overall Healthcare Expenditures in Europe, by Country, Through 2015
Table 21: Number of New Lung Cancer Cases in the U.K., by Gender, 2015
Table 22: Medicare Part B: Lung Cancer Drug Payment Limits, 2018
Table 23: Lung Cancer Drug Reimbursement in Germany, 2018
Table 24: Oncology Drugs Covered by China's National Insurance
Table 25: U.S. Patents on Lung Cancer Therapeutics, 2001-2018
Table 26: Patent Expiration of Lung Cancer Drugs
Table 27: List of FDA-Approved Drugs, Through 2018
Table 28: Lung Cancer Drugs Approved by Health Canada, Through 2018
Table 29: NSCLC Drugs Authorized by the EMA, Through 2018
Table 30: NSCLC Drugs Pending Approval by the EMA, Through 2018
Table 31: NSCLC Drugs Withdrawn by the EMA, Through 2018
Table 32: NSCLC Drugs Pending Application Withdrawal by the EMA, Through 2018
Table 33: SCLC Drugs Pending Withdrawal by the EMA, Through 2018
Table 34: Global Ranking of Lung Cancer Drug Companies, 2017
Table 35: Eli Lilly and Co.: Lung Cancer Marketed Products and Investigational Molecules, Through 2018
Table 36: AstraZeneca Pharmaceuticals: Lung Cancer Marketed Products and Investigational Molecules, Through 2018
Table 37: Lung Cancer Pipeline Drugs, Through 2018
Table 38: Clinical Efficacy of Select Third-Generation EGFR TKIs in Clinical Development
Table 39: AbbVie Inc.: Net Revenue, 2015-2017
Table 40: AbbVie Inc.: Lung Cancer Pipeline
Table 41: Astellas Pharma Inc.: Net Revenue, 2013-2017
Table 42: Astellas Pharma Inc.: Net Revenue, by Country/Region, 2014-2017
Table 43: AstraZeneca Plc: Net Revenue, 2014-2017
Table 44: AstraZeneca Plc: Marketed Products, 2018
Table 45: Bayer AG: Net Revenue, 2015-2017
Table 46: Bayer AG: Lung Cancer Pipeline Molecules
Table 47: Boehringer Ingelheim GmbH: Net Revenue, 2014-2016
Table 48: Boehringer Ingelheim GmbH: Marketed Product, 2018
Table 49: Bristol-Myers Squibb: Net Revenue, 2014-2016
Table 50: Bristol-Myers Squibb: Marketed Products, 2018
Table 51: Celgene Corp.: Net Revenue, 2015-2016
Table 52: Daiichi Sankyo Co., Ltd.: Net Revenue, 2015-2017
Table 53: Eli Lilly and Co.: Net Revenue, 2014-2017
Table 54: Eli Lilly and Co.: Net Revenue, by Segment, 2014-2016
Table 55: Eli Lilly and Co.: Net Revenue, by Oncology Drug, 2014-2016
Table 56: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, Through 2017
Table 57: Tarceva: Drug Revenue, by Country/Region, 2016-2017
Table 58: Merck & Co., Inc.: Net Revenue, 2014-2016
Table 59: Novartis International AG: Net Revenue, by Segment, Through 2017
Table 60: Novartis International AG: Oncology Drugs Revenue, 2015-2017
Table 61: Pfizer Inc.: Net Revenue, 2014-2017
Table 62: Pfizer Inc.: Oncology Drug Revenue, 2015-2017
Table 63: Pfizer Inc.: Oncology Drugs Revenue, 2015-2017
Table 64: Pfizer Inc.: Lung Cancer Marketed Products and Investigational Drug Candidates, 2018
Table 65: Acronyms Used in Global Lung Cancer Therapeutics Market
LIST OF FIGURES
Summary Figure: Global Market for Lung Cancer Therapeutics, by Type, 2017-2023
Figure 1: Gross Anatomy of the Human Lung
Figure 2: Share of Lung Cancer Types, by Histology
Figure 3: National Cancer Institute Research Funding, 2011-2016
Figure 4: U.S. Smoking Statistics, by Gender, 2017
Figure 5: Percentage Share of Lung Cancer Incidence, by Type of Mutation
Figure 6: Global Market for Non-Small Cell Lung Cancer Therapeutics, 2017-2023
Figure 7: Global Market for Small Cell Lung Cancer Therapeutics, 2017-2023
Figure 8: Percentage Share of Global Lung Cancer Incidence, by Country/Region, 2018
Figure 9: North American Market for Lung Cancer Therapeutics, 2017-2023
Figure 10: Percentage Share of Estimated Cancer Incidence in North America, by Type, 2018
Figure 11: Percentage Share of Estimated Cancer Incidence in the United States, by Type, 2018
Figure 12: European Market for Lung Cancer Therapeutics, 2017-2023
Figure 13: Per Capita Spending on Market Sectors in Europe, 2015
Figure 14: Incidence Rates of Lung Cancer in the U.K., by Gender, 1993-2015
Figure 15: Incidence of Lung Cancer in Scotland, by Cancer Stage, 2014-2015
Figure 16: Incidence of Lung Cancer in Italy, by Gender, 2010 and 2015
Figure 17: Percentage Share of Estimated Cancer Incidence in France, by Type, 2018
Figure 18: Percentage Share of Estimated Cancer Incidence in Germany, by Type, 2018
Figure 19: Asia-Pacific Market for Lung Cancer Therapeutics, 2017-2023
Figure 20: Percentage Share of Estimated Cancer Incidence in Asia-Pacific, by Type, 2018
Figure 21: Estimated Cancer Incidence in Asia-Pacific, by Country, 2018
Figure 22: Middle East and African Market for Lung Cancer Therapeutics, 2017-2023
Figure 23: Percentage Share of Estimated Cancer Incidence in Africa, by Type, 2018
Figure 24: South American Market for Lung Cancer Therapeutics, 2017-2023
Figure 25: Percentage Share of Estimated Cancer Incidence in South America, by Type, 2018
Figure 26: Drug Reimbursement Scenerio in Germany
Figure 27: Federal and Inter-Provincial Approval System for Cancer Drugs in Canada
Figure 28: Medical Device PMDA Approval Procedure
Figure 29: AbbVie Inc.: Revenue Share, by Region, 2016
Figure 30: Erlotinib: Revenue, 2015-2016
Figure 31: AstraZeneca Plc: Financial Performance, 2015-2017
Figure 32: AstraZeneca Plc: Financial Performance, 2013-2017
Figure 33: AstraZeneca Plc: Revenue Share, by Business Unit, 2017
Figure 34: AstraZeneca Plc: Revenue Share, by Country/Region, 2017
Figure 35: Bayer AG: Revenue Share, by Region, 2017
Figure 36: Bayer AG: Revenue Share, by Region, 2017
Figure 37: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2016
Figure 38: Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2016
Figure 39: Boehringer Ingelheim GmbH: Research and Development Expenditures, 2014-2016
Figure 40: Bristol-Myers Squibb: Revenue Share, by Country/Region, 2016
Figure 41: Bristol-Myers Squibb: Revenue Share, by Business Segment, 2016
Figure 42: Abraxane: Revenue, 2015-2017
Figure 43: Daiichi Sankyo Co., Ltd.: Revenue Share, by Business Segment, 2016
Figure 44: Eli Lilly and Co.: Revenue Share, by Country/Region, 2016
Figure 45: F. Hoffmann-La Roche Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016
Figure 46: F. Hoffmann-La Roche Ltd.: Lung Cancer Drug Revenue, 2016-2017
Figure 47: Merck & Co., Inc.: Revenue Share, by Business Segment, 2016
Figure 48: Merck & Co., Inc.: Keytruda Revenue, 2015-2017
Figure 49: Merck & Co., Inc.: Revenue Share, by Region, 2016
Figure 50: Pfizer Inc.: Revenue Share, by Region, 2016
Figure 51: Pfizer Inc.: Revenue Share, by Business Segment, 2016
Summary Figure: Global Market for Lung Cancer Therapeutics, by Type, 2017-2023
Figure 1: Gross Anatomy of the Human Lung
Figure 2: Share of Lung Cancer Types, by Histology
Figure 3: National Cancer Institute Research Funding, 2011-2016
Figure 4: U.S. Smoking Statistics, by Gender, 2017
Figure 5: Percentage Share of Lung Cancer Incidence, by Type of Mutation
Figure 6: Global Market for Non-Small Cell Lung Cancer Therapeutics, 2017-2023
Figure 7: Global Market for Small Cell Lung Cancer Therapeutics, 2017-2023
Figure 8: Percentage Share of Global Lung Cancer Incidence, by Country/Region, 2018
Figure 9: North American Market for Lung Cancer Therapeutics, 2017-2023
Figure 10: Percentage Share of Estimated Cancer Incidence in North America, by Type, 2018
Figure 11: Percentage Share of Estimated Cancer Incidence in the United States, by Type, 2018
Figure 12: European Market for Lung Cancer Therapeutics, 2017-2023
Figure 13: Per Capita Spending on Market Sectors in Europe, 2015
Figure 14: Incidence Rates of Lung Cancer in the U.K., by Gender, 1993-2015
Figure 15: Incidence of Lung Cancer in Scotland, by Cancer Stage, 2014-2015
Figure 16: Incidence of Lung Cancer in Italy, by Gender, 2010 and 2015
Figure 17: Percentage Share of Estimated Cancer Incidence in France, by Type, 2018
Figure 18: Percentage Share of Estimated Cancer Incidence in Germany, by Type, 2018
Figure 19: Asia-Pacific Market for Lung Cancer Therapeutics, 2017-2023
Figure 20: Percentage Share of Estimated Cancer Incidence in Asia-Pacific, by Type, 2018
Figure 21: Estimated Cancer Incidence in Asia-Pacific, by Country, 2018
Figure 22: Middle East and African Market for Lung Cancer Therapeutics, 2017-2023
Figure 23: Percentage Share of Estimated Cancer Incidence in Africa, by Type, 2018
Figure 24: South American Market for Lung Cancer Therapeutics, 2017-2023
Figure 25: Percentage Share of Estimated Cancer Incidence in South America, by Type, 2018
Figure 26: Drug Reimbursement Scenerio in Germany
Figure 27: Federal and Inter-Provincial Approval System for Cancer Drugs in Canada
Figure 28: Medical Device PMDA Approval Procedure
Figure 29: AbbVie Inc.: Revenue Share, by Region, 2016
Figure 30: Erlotinib: Revenue, 2015-2016
Figure 31: AstraZeneca Plc: Financial Performance, 2015-2017
Figure 32: AstraZeneca Plc: Financial Performance, 2013-2017
Figure 33: AstraZeneca Plc: Revenue Share, by Business Unit, 2017
Figure 34: AstraZeneca Plc: Revenue Share, by Country/Region, 2017
Figure 35: Bayer AG: Revenue Share, by Region, 2017
Figure 36: Bayer AG: Revenue Share, by Region, 2017
Figure 37: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2016
Figure 38: Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2016
Figure 39: Boehringer Ingelheim GmbH: Research and Development Expenditures, 2014-2016
Figure 40: Bristol-Myers Squibb: Revenue Share, by Country/Region, 2016
Figure 41: Bristol-Myers Squibb: Revenue Share, by Business Segment, 2016
Figure 42: Abraxane: Revenue, 2015-2017
Figure 43: Daiichi Sankyo Co., Ltd.: Revenue Share, by Business Segment, 2016
Figure 44: Eli Lilly and Co.: Revenue Share, by Country/Region, 2016
Figure 45: F. Hoffmann-La Roche Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016
Figure 46: F. Hoffmann-La Roche Ltd.: Lung Cancer Drug Revenue, 2016-2017
Figure 47: Merck & Co., Inc.: Revenue Share, by Business Segment, 2016
Figure 48: Merck & Co., Inc.: Keytruda Revenue, 2015-2017
Figure 49: Merck & Co., Inc.: Revenue Share, by Region, 2016
Figure 50: Pfizer Inc.: Revenue Share, by Region, 2016
Figure 51: Pfizer Inc.: Revenue Share, by Business Segment, 2016
